Conference highlights: The 81st Annual (Virtual) conference of the American diabetes association: June 25–29, 2021

Mohamed Suliman; Nagi Mohammed

doi:10.4103/jdep.jdep_31_21

Journal of Diabetes and Endocrine Practice, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Journal of Diabetes and Endocrine Practice 2021; 04(03): 143-147
DOI: 10.4103/jdep.jdep_31_21

Conference Highlights

Conference highlights: The 81^st Annual (Virtual) conference of the American diabetes association: June 25–29, 2021

Mohamed Suliman

Imperial College London Diabetes Centre, Al Ain, United Arab Emirates

,

Nagi Mohammed

Imperial College London Diabetes Centre, Al Ain, United Arab Emirates

› Institutsangaben

Abstract

The American Diabetes Association (ADA) annual conference is the most notable annual event in diabetes. Like many conferences in 2020 and 2021, it was held virtually due to the COVID-19 pandemic. In this highlights summary, we selected the sections that we felt are particularly relevant to practicing clinicians. The results of several long-awaited studies were released. These include the GRADE study, SURPASS, and STEP studies. The first ADA-European Association for the Study of Diabetes consensus on the management of type 1 diabetes was also aired during the conference. Besides, the AMPLITUDE-O study with new data on the cardiovascular and renal effects of Efpeglenatide was published. The role of Teplizumab for the prevention of type 1 diabetes and Volagidemab in patients with type 1 diabetes were discussed. Furthermore, the PROMISE study on the safety and accuracy of next-generation 180 days implantable continuous glucose monitoring systems was published. New news included advancing the role of glucagon in treating and preventing severe hypoglycemia. Furthermore, the Effects on heart failure with preserved ejection fraction from a pooled analysis of SOLOIST and SCORED studies were presented. Finally, data on Dapagliflozin in COVID-19 (DARE-19) and the STRENGTH versus REDUCE-IT studies were compared and contrasted. We hope to present a concise summary of the conference highlights for those who missed the live event.

Keywords

American Diabetes Association - diabetes - education - glucagon - research - trials

Volltext

Referenzen

References
1 Wexler DJ, Krause-Steinrauf H, Crandall JP, Florez HJ, Hox SH, Kuhn A, et al. Baseline characteristics of randomized participants in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE). Diabetes Care 2019;42:2098-107.
2 Frías JP. Tirzepatide: A glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab 2020;15:379-94.
3 Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials. Diabetes Ther 2021;12:143-57.
4 Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989.
5 Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA 2021;325:1414-25.
6 Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 2021;Jun 28. doi: 10.1056/NEJMoa2108269. Epub ahead of print.
7 Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, et al. Treatment of type 1 diabetes with teplizumab: Clinical and immunological follow-up after 7 years from diagnosis. Diabetologia 2019;62:655-64.
8 Garg SK, Liljenquist DR, Bode BW, Christiansen MP, Bailey TS, Brazg RL, et al. Evaluation of the next generation 180-day long-term implantable eversense CGM system: PROMISE study. ADA 2021;Abstract 149-OR.
9 Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, et al. 236-OR: Volagidemab, a human glucagon receptor antagonist, improves glycemic control in subjects with type 1 diabetes (T1D): A 12-week, randomized, double-blind, placebo-controlled trial. Diabetes 2021;70 Suppl 1. [doi: 10.2337/db21-236-OR].
10 Seaquist ER, Dulude H, Zhang XM, Rabasa-Lhoret R, Tsoukas GM, Conway JR, et al. Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting. Diabetes Obes Metab 2018;20:1316-20.
11 Pieber TR, Aronson R, Hövelmann U, Willard J, Plum-Mörschel L, Knudsen KM, et al. Dasiglucagon: A next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia results of phase 3 randomized double-blind clinical trial. Diabetes Care. 2021 Apr 21;44(6):1361–7.
12 Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:117-28.
13 Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 2021;384:129-39.
14 Kosiborod M, Berwanger O, Koch GG, Martinez F, Mukhtar O, Verma S, et al. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. Diabetes Obes Metab 2021;23:886-96.
15 Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11-22.
16 Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: The STRENGTH randomized clinical trial. JAMA 2020;324:2268-80.
17 Nissen SE, Lincoff AM, Wolski K, Ballantyne CM, Kastelein JJ, Ridker PM, et al. Association between achieved ω-3 fatty acid levels and major adverse cardiovascular outcomes in patients with high cardiovascular risk: A secondary analysis of the STRENGTH trial. JAMA Cardiol. 2021 May 16: e211157. doi: 10.1001/jamacardio.2021.1157. Epub ahead of print.